Thermedical has treated the first patient in a pivotal clinical trial of its saline-enhanced radiofrequency (SERF) ablation ...

MIT-alumni-founded Thermedical advances novel deep-tissue ablation technology to address critical unmet needs in severe ventricular tachycardia ...

UT Health San Antonio Multispecialty and Research Hospital became the first in South Texas to use an emerging and ...

Shorter, nanosecond pulses for treating atrial fibrillation differentiate the company’s approach from existing pulsed field ...

Profound Medical (Nasdaq:PROF) announced today that it sold shares of common stock worth proceeds of up to $40 million.

Trigeminal neuralgia (TN) is a debilitating, chronic syndrome that causes sudden, severe, electric shock-like pain in the face. While TN isn’t life-threatening, it can severely alter quality of life ...

The FDA said it plans to accept new forms of real-world evidence in product applications, starting with a subset of medical ...

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

HRS/ACC statement guides expanded access for intracardiac ablation procedures in ambulatory surgical centers for appropriate patients.

Discover NeuroOne's record-breaking Q4 2025 earnings, major product launches, and strategic partnership growth in pain management and drug delivery.

NeuroOne Medical Technologies Corp (NMTC) reports significant revenue growth, improved margins, and strategic progress despite challenges in compliance and international expansion.

Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.